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INTRODUCTION
Chronic graft-versus-host disease (cGVHD) is a serious
late complication of allogeneic transplantation because of its
inﬂuence on health, relapse, and survival [1-8]. Large obser-
vational studies identify cGVHD as the leading cause of
nonrelapse deaths occurring more than 2 years posttrans-
plantation [8]. However, it is difﬁcult to determine optimal
management strategies or to test new strategies, because of
the great variability in organ involvement and the waxing
and waning natural history of cGVHD. Systemic immuno-
suppression is the basis of treatment, yet there is a delicate
balance between controlling cGVHD symptoms and
increasing susceptibility to infections, a major cause of death
in these patients. Central to managing cGVHD is the ability
to (1) recognize its initial manifestations and establish the
diagnosis; (2) assess its severity, trajectory, and response to
therapy; and (3) appreciate its impact on survival and quality
of life. A 1989 survey of transplantation physicians showed
moderate levels of agreement about cGVHD diagnosis and
management [9]. We undertook a similar survey to provide
an updated cross-sectional view of current practices.
A 6-page survey covering diagnosis, treatment, and
management of cGVHD was designed, pilot tested, and
mailed to US transplantation centers. The survey also
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ABSTRACT
Chronic GVHD (cGVHD) is a potentially devastating late complication of allogeneic stem cell transplantation. To
better understand current diagnostic and treatment practices regarding this complication, we mailed a self-administered
survey to 188 adult and pediatric transplantation programs. The survey collected data on experience with therapies
for cGVHD and presented 6 vignettes to assess agreement about the diagnosis, clinical management, grading, and
prognosis of patients with symptoms of cGVHD. Response rate to the survey was 51%. Of the respondents, 28% felt
they had “great success” in treating patients with systemic corticosteroids, and 13% had similar success with cyclo-
sporine or mycophenolate mofetil; less success and experience were reported with other agents. Respondents estimated
an average 3-year, nonrelapse mortality of 16% (95% CI, 14%-19%) for patients assessed to have limited disease and
39% (95% CI, 36%-43%) for extensive disease. Analysis of responses to the 6 vignettes showed that agreement was
greatest for supportive care issues, willingness to enroll patients in clinical trials, and use of systemic immunosup-
pression for symptomatic cGVHD. Less agreement was seen for diagnosis and management when cGVHD manifes-
tations were atypical or less severe, the decision of whether to taper immunosuppression in the face of stable symptoms,
and for assignment of mild, moderate, or severe cGVHD grades. Most respondents were willing to use systemic
immunosuppression to treat symptoms that they believed to be caused by cGVHD, but differences of opinion about
cGVHD diagnosis and disease activity resulted in significant practice variation. Low estimates of treatment success
were noted and reflected an overall pessimism about the success of therapy for cGVHD. We conclude that studies
defining appropriate diagnostic pathways, criteria for disease activity, and prognosis could help standardize manage-
ment of cGVHD. There is an urgent need to develop and test new approaches to treat cGVHD.
KEY WORDS
Chronic graft-versus-host disease • Allogeneic stem cell transplantation
Biology of Blood and Marrow Transplantation 8:32-39 (2002)
© 2002 American Society for Blood and Marrow Transplantation ASBMT
cGVHD Practice Survey
33B B & M T
included 6 vignettes in which respondents were asked to
grade cGVHD severity and to provide an estimate of 3-year
nonrelapse mortality. Results from this survey allow com-
ment on areas of agreement and controversy and identify
areas for future work.
MATERIALS AND METHODS
Survey Development
All authors contributed to the design of the survey
instrument, which was modeled after a similar study pub-
lished in 1989 by Atkinson et al. [9]. The survey asked about
the use of therapeutic agents to manage cGVHD and the
perceived success of these interventions. Four response cate-
gories were offered: “No, I have not used this agent” and
“Yes, I have used this agent with (1) no, (2) some, or (3)
great success.” A separate section presented 9 clinical man-
agement problems (persistent erythema, pruritis, mouth
sores, keratoconjunctivitis, chronic diarrhea, joint contrac-
tures, vaginal strictures, bronchiolitis obliterans, and
scleroderma) and asked about any locally developed or novel
therapies. Six vignettes were presented to span the spectrum
of cGVHD diagnosis, management, and severity assessment,
and respondents were asked to estimate 3-year nonrelapse
mortality for each case. Finally, center and practitioner
information was collected. Pilot testing was performed to
assess comprehension and clarity. The clinical vignettes and
questions are reproduced in the Appendix.
Data Collection
The survey was initially mailed to centers in the United
States that participate in the International Bone Marrow
Transplant Registry (IBMTR) and the Pediatric Blood and
Marrow Transplant Consortium. A drawing for a cash prize
was used as an incentive to encourage participation. Nonre-
spondents received 2 e-mailed reminders and another copy
of the survey (attached electronically). Participants were sur-
veyed between December 2000 and February 2001.
Biostatistical Analysis
Descriptive statistics are reported for center characteris-
tics, use of therapies and their perceived benefits, and
responses to vignettes. Vignette items were classified into
1 of 5 categories: clinical diagnosis (7 questions), use of
diagnostic tests (6 questions), clinical management (22 ques-
tions), grading and prognosis (18 questions), and supportive
care (7 questions including referral to specialists, prophylac-
tic antibiotics, and immunizations). When answers were
dichotomous, the degree of agreement was quantified
among respondents by calculating the percentage agreeing.
We interpreted degree of agreement in the following way:
50% to 60% = disagreement (–), because this level is no bet-
ter than chance; 61% to 70% = low agreement (+); 71% to
80% = moderate agreement (++); 81% to 90% = strong
agreement (+++); and ≥91% = very strong agreement (++++).
Practitioners were divided into higher volume (caring for at
least 10 patients with cGVHD) and lower volume and pri-
marily adult versus pediatric practices. Levels of agreement
were compared among these groups.
Associations between assessed severity of cGVHD and
nonrelapse mortality estimates were calculated for each
vignette separately, then summarized across vignettes and
respondents. The pooled estimates were calculated by gen-
erating 1 estimate per respondent for each severity category
(limited, extensive, mild, moderate, and severe cGVHD)




A total of 220 surveys were mailed to centers. Of these
surveys, 32 were subsequently deemed to be ineligible (cen-
ters performed autologous procedures only, mailings sent to
different individuals practicing at the same center, or institu-
tion no longer performing transplantation procedures).
Among the eligible institutions, there were 94 responders
(50%) with evaluable surveys, 2 responders (1%) with
unevaluable surveys, and 92 nonresponders (49%). The
median number of allogeneic procedures performed annually
at each respondent center was 30, and the median number of
patients with cGVHD cared for by each center was esti-
mated at 20. Respondents estimated that they personally
took care of a median of 10 patients with cGVHD. Multi-
ple methods of GVHD prophylaxis were used at centers,
including cyclosporine (94%), tacrolimus (61% of centers),
standard methotrexate (76%), mini-methotrexate (41%), and
T-cell depletion (46%). Only 18% of centers reported hav-
ing research protocols to treat cGVHD, and 7% had studies
to prevent cGVHD. Of the respondents, 93% stated that
they would be interested in participating in a group dedi-
cated to multicenter studies of cGVHD, such as evaluating
new grading schemes, management strategies, new drugs or
combinations of drugs, or collecting serum or tissue samples.
There was no evidence for systematically different
responses from higher volume versus lower volume or adult
versus pediatric practices, and responses were combined for
analysis.
Diagnosis of cGVHD
Agreement about the clinical diagnosis and use of biop-
sies to diagnose cGVHD was moderate, with 79% average
agreement (range, 54%-96%) for the 7 questions regarding
clinical diagnosis and 76% (range, 60%-93%) for the
6 questions about use of diagnostic tests. There was very
strong agreement that a persistent conﬂuent rash present on
day 120 was cGVHD (item 1.4, 91% agreement) and that
bilateral buccal ulcers with negative herpes simplex virus
(HSV) culture results in month 14 was cGVHD (item 1.8,
96%). Most respondents agreed that a patient presenting on
day 190 with pruritis, eosinophilia, and thrombocytopenia
had cGVHD (item 6.1, 80%). In contrast, there was dis-
agreement about whether an isolated elevated alkaline phos-
phatase level on day 160 posttransplantation was cGVHD
(item 5.2, 54%). Agreement about use of diagnostic tests
varied. There was very strong agreement about performing
a bronchoalveolar lavage on day 140 posttransplantation for
dyspnea on exertion with interstitial inﬁltrates and negative
sputum culture results (item 3.3, 93%) and about perform-
ing a skin biopsy on day 140 for an isolated rash involving
the arms, chest, upper back, and thighs (item 4.1, 89%).
However, there was low agreement on whether a liver
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biopsy should be performed on day 180 posttransplantation
for an isolated direct hyperbilirubinemia with normal ultra-
sound (item 1.5, 60%).
Management of cGVHD
Corticosteroids (systemic and topical), cyclosporine,
tacrolimus, mycophenolate mofetil, psoralen and UV-A
(PUVA), thalidomide, antithymocyte globulin, extracorpo-
real photopheresis, ursodeoxycholic acid, daclizumab, aza-
thioprine, hydroxychloroquine, and inﬂiximab had some or
great success by 20% or more of respondents. However, of
these agents, only systemic corticosteroids, cyclosporine,
and mycophenolate mofetil were deemed of “great success”
by more than 10% of the respondents (Figure).
Suggestions for managing persistent erythema, pruritis,
mouth ulcers, keratoconjunctivitis, chronic diarrhea, joint
contractures, vaginal strictures, bronchiolitis obliterans, and
scleroderma were solicited, and the list of responses is avail-
able from the authors. In general, answers could be divided
into recommendations for specific systemic immunosup-
pressive agents, supportive care (including nutrition, mas-
sage, physical therapy, and assistive devices), local therapies,
and infection-preventive strategies.
The 22 items from the vignettes considered to measure
management of cGVHD showed moderate agreement
(mean, 76%; range, 53%-97%). Very strong agreement was
found for enrolling patients in phase I, II, and III clinical
trials of therapy for cGVHD, except in cases of asympto-
matic cGVHD (item 5.4, 65%) or atypical manifestations
(item 6.5, 53%). There was also very strong agreement for
increasing or starting immunosuppressive therapy for a con-
fluent rash involving the chest and back on day 160 with
associated thrombocytopenia (item 4.4, 91%), for severe
sclerodermatous changes of the lower extremity (item 2.5,
96%), and for symptomatic interstitial inﬁltrates once infec-
tion was ruled out (item 3.5, 97%). Most respondents would
also use systemic immunosuppression to treat dry eyes and
mouth and oral lichen planus at 9 months (item 2.3, 85%).
Most respondents would taper systemic immunosuppression
if a biopsy-proven lichenoid skin rash had resolved after
2 weeks of steroid therapy (item 5.1, 86%) but would not
taper immunosuppression 3 months after interstitial pneu-
monitis if a patient was still symptomatic (item 3.6, 82%).
Areas of less agreement about cGVHD management
were identiﬁed and could be categorized as: (1) disagreement
about cGVHD diagnosis (with high correlation between
diagnosis of cGVHD and decision to start or increase sys-
temic treatment); (2) use of topical therapies, such as corti-
costeroids or PUVA; and (3) whether to taper medications
when cGVHD manifestations were stable. Speciﬁcally, there
was low agreement about the need for increased immuno-
suppression for isolated oral lichen planus on day 70 (item
3.2, 53%), the usefulness of topical steroids (item 4.3, 58%)
or PUVA for conﬂuent erythema in the setting of thrombo-
cytopenia (item 4.5, 61%), and the decision to taper steroids
with unchanged sclerodermatous manifestations after
3 months (item 2.8, 68%) or with increasing alkaline phos-
phatase level as an isolated ﬁnding (item 5.3, 61%).
Experience and perceived success with the 15 most common therapies for cGVHD.
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Stratification of management decisions by diagnostic
impressions showed that once cGVHD was believed to
be present, respondents were willing to treat aggressively
with systemic immunosuppression. In general, there was no
evidence that respondents were willing to tolerate some
manifestations to spare patients from further immunosup-
pression. The 1 exception was mouth ulcers, fatigue, and
weight loss at month 14 (item 1.9, 64%), for which most
respondents agreed that the patient had cGVHD, but many
would not treat systemically.
Supportive Care
There was a generally high level of agreement about
appropriate supportive care for patients with cGVHD (88%;
range, 78%-98%). Respondents were likely to vaccinate
patients when appropriate (item 5.5, 88%); avoid vaccination
with live viruses, such as measles, mumps, rubella (MMR)
(item 4.8, 98%); prescribe penicillin (item 2.4, 89%) and
pneumocystosis prophylaxis (item 2.7, 96%); and refer to
specialists (item 2.2, 93%). There was only moderate agree-
ment about tetanus vaccination at day 360 (item 4.7, 78%).
Assessment of Severity and Survival
Agreement about limited and extensive grading was rea-
sonably good for the 6 vignettes (82%; range, 72%-92%),
but agreement according to mild, moderate, and severe
grading was not as good (Table). On average, respondents
estimated a 3-year nonrelapse mortality of 16% (95% CI,
14%-19%) for patients with limited disease and 39% (95%
CI, 36%-43%) for those with extensive disease. For patients
classiﬁed as having mild, moderate, or severe cGVHD, the
estimates were 12% (95% CI, 10%-14%), 28% (95% CI,
25%-31%), and 48% (95% CI, 44%-52%), respectively.
DISCUSSION
We report the results of a mailed survey sent to adult and
pediatric transplantation centers participating in the IBMTR
or the Pediatric Blood and Marrow Transplant Consortium.
Agreement was highest for supportive care measures, assign-
ment of limited/extensive grades, and management with
immunosuppression when the diagnosis of cGVHD was felt
to be clear and the manifestations severe. Areas of low-to-
moderate agreement, or even frank disagreement, were iden-
tiﬁed in situations in which the presentation of cGVHD was
atypical, manifestations were less severe, or stable functional
limitations persisted, similar to the ﬁndings of Atkinson and
colleagues [9]. In these circumstances, the presence or
absence of cGVHD was a major source of disagreement, and
the decision to treat correlated signiﬁcantly with a diagnosis
of cGVHD. Because cGVHD can often be deﬁnitively diag-
nosed on biopsy, our ﬁndings support the use of biopsy as a
routine diagnostic procedure in the evaluation of cGVHD.
Although we hypothesized that practice variation might
result from decisions to treat certain manifestations less
aggressively because of concern about increasing suscepti-
bility to infections, we found that most respondents were
willing to treat with systemic immunosuppression if they
believed cGVHD was present. The sole exception was oral
ulcers, fatigue, and weight loss in month 14. Although many
respondents identiﬁed this group of symptoms as cGVHD,
fewer indicated that they would start systemic immunosup-
pressive therapy based on these symptoms.
Although respondents did not have high agreement on
whether patients presented in the vignettes had mild, moder-
ate, or severe cGVHD, remarkably consistent estimates of
3-year nonrelapse mortality were associated with each sever-
ity grading. Pooled estimates of 3-year nonrelapse mortality
Estimates of cGVHD Severity and Prognosis*
3-Year Nonrelapse 3-Year Nonrelapse
Vignette Percentage or Mortality, Mean, Percentage or Mortality, Mean,
No. Grade No. of Respondents % (95% CI) Grade No. of Respondents % (95% CI)
1 Limited 28% 14 (10-19) Mild 20% 15 (9-22)
Extensive 72% 30 (26-33) Moderate 74% 28 (24-31)
Severe 6% 52 (35-69)
2 Limited 15% 23 (14-32) Mild 2% 16 (0-64)
Extensive 85% 35 (31-39) Moderate 46% 30 (25-35)
Severe 52% 38 (33-44)
3 Limited 15% 50 (33-66) Mild — —
Extensive 85% 48 (44-53) Moderate 29% 33 (26-41)
Severe 71% 54 (49-59)
4 Limited 8% 29 (4-53) Mild — —
Extensive 92% 45 (40-49) Moderate 36% 31 (25-37)
Severe 64% 51 (46-57)
5 Limited 86% 12 (10-13) Mild 74% 11 (9-13)
Extensive 14% 21 (13-28) Moderate 26% 18 (13-23)
Severe — —
6 Limited 28% 16 (11-22) Mild 8% 17 (7-26)
Extensive 72% 37 (31-42) Moderate 49% 22 (18-26)
Severe 43% 45 (37-53)
Summary Limited 76 16 (14-19) Mild 65 12 (10-14)
Extensive 87 39 (36-43) Moderate 85 28 (25-31)
Severe 76 48 (44-52)
*Percentage of respondents selecting each severity category (limited/extensive and mild/moderate/severe) for the 6 vignettes, and the mean
3-year, nonrelapse mortality estimate. Summary statistics are pooled across respondents and vignettes.
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ranged from 12% for patients assessed with mild disease to
48% for those thought to have severe disease. These esti-
mates were actually very similar to survival data from a retro-
spective study by the IBMTR and the National Marrow
Donor Program (S.J.L., unpublished data, 2001). The high
mortality associated with cGVHD supports aggressive clini-
cal research efforts in this area. Of the respondents to our
survey, 93% expressed interest in participating in multicenter
studies of grading schemes, management strategies, and new
drugs or combinations of drugs, a result consistent with our
impression that the transplantation community recognizes a
need to study ways of improving therapy for cGVHD.
The major limitations of our study were the data collec-
tion mechanism (a mailed survey to US transplantation cen-
ters only) and the 50% response rate (despite 3 attempts to
contact physicians and offering an incentive to participate).
Thus our observations are based on a self-selected subset of
transplantation programs and may not adequately summa-
rize current practice in the United States. Also, clinical deci-
sions were assessed using a series of vignettes, which may
not recapitulate actual practice. Nevertheless, our results
suggest that a major source of practice variation may reﬂect
different thresholds for diagnosing cGVHD and variation in
assessments of disease severity and trajectory. Respondents
generally followed the tenet of aggressive systemic immuno-
suppression if they believed cGVHD to be active. Future
studies to standardize the diagnosis and grading of cGVHD
and to develop better therapy for cGVHD are needed.
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APPENDIX
The following 6 vignettes were developed to represent
common, and often difﬁcult, clinical scenarios. Please read
each case carefully, then indicate your choices by circling
1 answer for each question. Unless otherwise noted, “sys-
temic immunosuppression” refers to corticosteroids, cyclo-
sporine, tacrolimus, mycophenolate mofetil, rapamycin, or
azathioprine.
Vignette 1: 35-year-old man, underwent matched-unrelated BMT for CML, methotrexate/cyclosporine*
Day 12: Febrile neutropenia, started β-lactam and aminoglycoside
Day 18: Engraftment
Day 21: Macular-papular rash involving 18% of body, antibiotics changed
Day 23: Progression of rash to involve 54% of body surface
Day 120: Persistent confluent erythema
Day 180: Feels well, no rash, total bilirubin 5.4, direct 4.4, right upper quadrant ultrasound normal
Month 14: Feels tired, no rash, normal bilirubin, bilateral buccal mouth ulcers noted, HSV culture negative, 2-kg weight loss over 1 month
No Yes Agreement
1.1 I would perform a skin biopsy on day 21 30 61 0.67 +
1.2 I would start steroids on day 21 69 20 0.78 ++
1.3 I would start steroids on day 23 12 76 0.87 +++
1.4 This patient had cutaneous cGVHD day 120 7 77 0.91 ++++
1.5 I would perform a liver biopsy on day 180 34 53 0.60 +
1.6 This patient had hepatic cGVHD on day 180 19 64 0.76 ++
1.7 I would start or increase systemic immunosuppression on day 180 24 62 0.72 ++
1.8 This patient had oral cGVHD in month 14 5 83 0.96 ++++
1.9 I would start or increase systemic immunosuppression in month 14 28 52 0.64 +
1.10 Maximum grade of cGVHD None (0%) Limited (28%) Extensive (72%) 0.72 ++
1.11 Maximum severity of cGVHD None (0%) Mild (20%) Moderate (74%) Severe (6%)
1.12 Estimated nonrelapse mortality within the next 3 years 20% (5%-75%), mean 26% (n = 86)
*Numbers for maximum grade and severity of GVHD and for the estimated 3-year nonrelapse mortality may not add up to 100% because
of rounding.
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Vignette 2: 22-year-old man with aplastic anemia, underwent matched-sibling BMT, methotrexate/cyclosporine*
Day 20: Engraftment
Month 9: Dry eyes and mouth, oral lichen planus
Month 13: Severe sclerodermatous changes and loss of hair on lower extremities
Month 16: Scleroderma unchanged
No Yes Agreement
2.1 I would perform a Schirmer’s test at 9 months 26 64 0.73 ++
2.2 I would refer this patient to an ophthalmologist at 9 months 6 84 0.93 ++++
2.3 I would start or increase systemic immunosuppression at 9 months 14 77 0.85 +++
2.4 I would start or continue penicillin prophylaxis at 9 months 9 83 0.89 +++
2.5 I would start or increase systemic immunosuppression at 13 months 4 87 0.96 ++++
2.6 I would be willing to enroll this patient in a Phase II clinical trial of a novel 6 84 0.93 ++++ 
immunosuppressive medication at month 13
2.7 I would start or continue pneumocystis pneumonia prophylaxis at 4 85 0.96 ++++ 
13 months
2.8 I would taper systemic immunosuppression at month 16 57 29 0.68 +
2.9 Maximum grade of cGVHD None (0%) Limited (14%) Extensive (86%) 0.86 +++
2.10 Maximum severity of cGVHD None (0%) Mild (2%) Moderate (48%) Severe (50%)
2.11 Estimated nonrelapse mortality within the next 3 years 30% (2.5%-95%), mean 33% (n = 86)
*Numbers for maximum grade and severity of GVHD and for the estimated 3-year nonrelapse mortality may not add up to 100% because
of rounding.
Vignette 3: 46-year-old woman with AML in second remission, underwent mismatched-related BMT from daughter, methotrexate/tacrolimus, patient and
donor CMV negative*
Day 24: Engraftment
Day 45: Acute GVHD, resolved with steroids, taper in progress
Day 70: Oral lichen planus
Day 140: Dyspnea on exertion, chest x-ray and computed tomography showed interstitial infiltrates, sputum cultures negative
Day 240: Unable to do strenuous tasks, pulmonary function tests show an FEV1 of 40%
Day 380: Stable clinical status, pulmonary function tests show an FEV1 of 42%
No Yes Agreement
3.1 This patient had cGVHD on day 70 21 71 0.77 ++
3.2 I would start or increase systemic immunosuppression on day 70 43 47 0.53 –
3.3 I would perform a bronchoalveolar lavage on day 140 6 85 0.93 ++++
3.4 I would perform a transbronchial biopsy on day 140 22 66 0.74 ++
3.5 I would start or increase systemic immunosuppression on day 142 if 3 88 0.97 ++++ 
cultures for infectious organisms are negative
3.6 I would taper systemic immunosuppression on day 240 73 16 0.82 +++
3.7 I would be willing to enroll this patient in a Phase I clinical trial of a 8 83 0.92 ++++
novel immunosuppressive medication on day 240
3.8 I would taper systemic immunosuppression on day 380 24 65 0.73 ++
3.9 Maximum grade of cGVHD None (2%) Limited (16%) Extensive (81%) 0.83 +++
3.10 Maximum severity of cGVHD None (0%) Mild (0%) Moderate (30%) Severe (70%)
3.11 Estimated nonrelapse mortality within the next 3 years 50% (10%-95%), mean 48% (n = 86)
*Numbers for maximum grade and severity of GVHD and for the estimated 3-year nonrelapse mortality may not add up to 100% because
of rounding.
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Vignette 4: 50-year-old woman, underwent matched-sibling peripheral blood transplantation for refractory anemia with excess blasts, methotrexate/tacrolimus*
Day 16: Engraftment
Day 30: Acute GVHD of skin, resolved with steroids
Day 140: Feels well, macular-papular pruritic rash involving arms, chest, upper back, upper thighs
Day 160: Confluent erythema involving the chest and back, platelets 80,000/µL
Day 360: Confluent erythema over chest and back, chronic diarrhea, 10-kg weight loss
No Yes Agreement
4.1 I would perform a skin biopsy on day 140 9 82 0.89 ++++
4.2 I would start or increase systemic immunosuppression on day 140 22 68 0.77 ++
4.3 I would prescribe topical steroids on day 140 35 53 0.58 +
4.4 I would start or increase systemic immunosuppression on day 160 9 81 0.91 ++++
4.5 I would prescribe PUVA on day 160 52 36 0.61 +
4.6 I would be willing to enroll this patient in a Phase III clinical trial of 4 87 0.97 ++++
standard versus more intensive immunosuppression on day 160
4.7 I would administer the tetanus vaccine on day 360 69 21 0.78 ++
4.8 I would administer the measles, mumps, rubella vaccine on day 360 88 2 0.98 ++++
4.9 Maximum grade of cGVHD None (0%) Limited (8%) Extensive (92%) 0.92 ++++
4.10 Maximum severity of cGVHD None (0%) Mild (1%) Moderate (37%) Severe (62%)
4.11 Estimated nonrelapse mortality within the next 3 years 40% (5%-95%), mean 43% (n = 88)
*Numbers for maximum grade and severity of GVHD and for the estimated 3-year nonrelapse mortality may not add up to 100% because
of rounding.
Vignette 5: 21-year-old woman, Philadelphia chromosome–positive ALL, underwent matched-sibling BMT, mini-methotrexate/tacrolimus*
Day 14: Engraftment
Day 130: Macular-papular rash on back, biopsy showed lichenoid cGVHD
Day 144: Rash resolved on 1 mg/kg steroids
Day 160: Elevation of alkaline phosphatase, 2× normal, otherwise well
Day 174: Elevation of alkaline phosphatase, 3× normal, otherwise well
Day 365: Returned to school
No Yes Agreement
5.1 I would taper steroids on day 144 13 78 0.86 +++
5.2 This patient had liver cGVHD on day 160 40 42 0.54 –
5.3 I would taper steroids on day 174 54 35 0.61 +
5.4 I would be willing to enroll this patient in a phase II clinical trial of a 58 32 0.65 +
novel immunosuppressive medication on day 174
5.5 I would administer the influenza vaccine on day 365 12 79 0.88 +++
5.6 I would administer the measles, mumps, rubella vaccine on day 365 70 19 0.79 ++
5.7 Maximum grade of cGVHD None (4%) Limited (83%) Extensive (13%) 0.86 +++
5.8 Maximum severity of cGVHD None (4%) Mild (72%) Moderate (24%) Severe (0%)
5.9 Estimated nonrelapse mortality within the next 3 years 10% (2.5%-50%), mean 13% (n = 83)
*Numbers for maximum grade and severity of GVHD and for the estimated 3-year nonrelapse mortality may not add up to 100% because
of rounding.
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Vignette 6: 5-year-old boy with AML in second remission, underwent transplantation from matched sibling, methotrexate/cyclosporine*
Day 19: Engrafted
Day 25: Acute GVHD of skin, resolved on steroids
Day 180: Steroids and cyclosporine discontinued
Day 190: Pruritis, eosinophilia, platelets 75,000/µL
Day 200: Presented with chest pain, dyspnea on exertion, echocardiogram showed large pericardial effusion, pericardiocentesis showed 
transudative fluid, cultures, and cytology negative
Day 210: Pericardial fluid reaccumulated, pericardial window placed, no further symptoms
No Yes Agreement
6.1 This patient had cGVHD on day 190 17 72 0.80 +++
6.2 I would start or increase systemic immunosuppression on day 190 21 67 0.75 ++
6.3 This patient had cGVHD on day 200 18 66 0.78 ++
6.4 I would start or increase systemic immunosuppression on day 200 25 60 0.70 ++
6.5 I would be willing to enroll this patient in a Phase II clinical trial of a 39 47 0.53 – 
novel immunosuppressive medication on day 200
6.6 Maximum grade of cGVHD None (15%) Limited (23%) Extensive (62%) 0.73 ++
6.7 Maximum severity of cGVHD None (12%) Mild (7%) Moderate (44%) Severe (37%)
6.8 Estimated nonrelapse mortality within the next 3 years 25% (5%-80%), mean 31% (n = 70)
*Numbers for maximum grade and severity of GVHD and for the estimated 3-year nonrelapse mortality may not add up to 100% because
of rounding.
